With its Remicade biosimilar stymied by the brand, Pfizer sues Johnson & Johnson for 'anticompetitive' dealmaking
admin 20th September 2017 Uncategorised 0Two pharma giants are squaring off on a first-of-a-kind lawsuit over the budding biosimilar business in the U.S. Unable to make much headway with its first biosimilar rollout, Pfizer accuses Johnson & Johnson of striking “exclusionary contracts” on its megablockbuster Remicade to quash that competition.
More: With its Remicade biosimilar stymied by the brand, Pfizer sues Johnson & Johnson for 'anticompetitive' dealmaking
Source: fierce